Projects funded under Horizon 2020 are not intended to support the direct market introduction of new products. The applicable rules do not foresee conditions being attached to EU-funded research projects on pricing of products that may come out of such projects.

Projects funded in the area of health research and innovation address the specific objective to improve the lifelong health and well-being of all. These projects contribute to the objectives[1] of Horizon 2020[2] and the priorities of the Commission, in particular regarding Jobs, Growth and Investment[3]. Return on investment from such EU-funded health research consists in creating jobs and economic growth, maintaining leadership of EU health research and innovation, supporting academic research institutions and SMEs[4], and increasing competitiveness of industry with the pharmaceutical industry being one of the EU's key industries.

Information on funding for projects supported through Horizon 2020 is fully transparent[5]. Beyond the costs for the projects to be implemented under an EU research grant, Horizon 2020 does not provide for the obligation of beneficiaries to disclose costs not related to the implementation of such grants.

According to Article 168(7) of the Treaty on the Functioning of the European Union [6], Member States are responsible for the definition of their health policies and for the organisation and delivery of health services. This includes measures regulating the prices of medicines and their inclusion in health insurance systems.

• [1] The general objective of Horizon 2020 is to build a society and a world-leading economy based on knowledge and innovation across the whole Union, while contributing to sustainable development. It will support the Europe 2020 strategy and other Union policies as well as the achievement and functioning of the European Research Area (ERA).
• [2] The EU Framework Programme for Research and Innovation (2014-2020) — OJ L 347, 20.12.2013
• [3] https://ec.europa.eu/priorities/index_en
• [4] Small and medium-sized enterprises
• [5] Through the Community Research and Development Information Service — http://cordis.europa.eu/
• [6] OJ C 326, 26.10.2012